NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-003-2006-0-US-05 Antibodies and Immunotoxins that Target Human Glycoprotein NMB US DIV 13/897,587 9115196 Issued PDF
NINR E-349-2013-0-US-01 Altered Expression Of Mirna And Mrna For Identification And Therapy In Digestive And Liver Disorders US 61/825,154 Abandoned
NINR E-349-2013-1-US-01 ALTERED EXPRESSION OF MIRNA AND MRNA FOR IDENTIFICATION AND THERAPY IN
DIGESTIVE AND LIVER DISORDERS 		US 61/825,489 Abandoned
NIAID E-089-2002-1-US-48 Dengue Tetravalent Vaccine Containing A Common 30 Nucleotide Deletion In The 3-UTR Of Dengue Types 1,2,3, And 4, Or Antigenic Chimeric Dengue Viruses 1,2,3, And 4 US REISSUE 13/896,388 46641 Expired PDF
NIAID E-089-2002-1-US-47 Dengue Tetravalent Vaccine Containing A Common 30 Nucleotide Deletion In The 3'-UTR Of Dengue Types 1,2,3, And 4, Or Antigenic Chimeric Dengue Viruses 1,2,3, And 4 US REISSUE 13/896,384 46631 Expired PDF
NIDDK E-284-2008-0-US-08 Low Molecular Weight Thyroid Stimulating Hormone Receptor (TSHR) Agonists US CON 13/897,330 9187457 Issued PDF
NIAID E-120-2001-0-US-37 Recombinant Attenuated Dengue Viruses Comprising A Deletion in the 3' Untranslated Region and Additional Attenuating Mutations Induced by Chemical Mutagenesis US REISSUE 13/896,409 45123 Expired PDF
NIAID E-120-2001-0-US-35 Attenuated Dengue Virus Comprising Mutations in the NS3 Gene US REISSUE 13/896,411 045053 Expired PDF
NIAID E-120-2001-0-US-36 DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES US REISSUE 13/896,396 45016 Expired PDF
NCI E-164-2012-0-PCT-02 Nanoparticles with Enhanced Entry into Cancer Cells PCT PCT PCT/US2013/041542 Expired
NCI E-005-2011-0-US-01 SOLUBLE CD27 (SCD27) AND THE USE THEREOF US 61/824,898 Abandoned
NIAID E-139-2006-0-US-12 Development Of Dengue Virus Vaccine Components US REISSUE 13/895,908 046042 Issued PDF
NEI E-056-2008-0-US-04 MIR 204, MIR 211, Their Anti-MIRS, and Therapeutic Uses of Same US DIV 13/895,557 8710026 Issued PDF
NCI E-093-2013-0-US-01 Compounds For Inhibiting Drug-Resistant Strains Of HIV-1 Integrase US 61/824,306 Abandoned
NCI E-273-2011-0-PCT-02 Cross-Reactive Antibodies Against Dengue Viruses And Uses Thereof PCT PCT PCT/US13/40966 Expired
NCI E-025-2011-2-US-03 Antibodies To Tumor Endothelial Marker 8 US National Stage 13/884,899 9309322 Issued PDF
NIAID E-214-2015-0-CA-08 Conformationally Specific Viral Immunogens CA National Stage 2873048 Issued
NIAID E-214-2015-0-EP-06 Conformationally Specific Viral Immunogens EP National Stage 13787969.8 Issued
NIAID E-214-2015-0-PCT-03 Conformationally Specific Viral Immunogens PCT PCT PCT/US2013/040228 Expired
NIAID E-214-2015-0-US-04 Conformationally Specific Viral Immunogens US ORD 13/890,465 Abandoned
NIA E-260-2011-0-US-02 SYNTHESIS OF FLUOROARACHIDONIC AND METHODS OF USE THEREOF US National Stage 13/890,884 Abandoned
NCI E-194-2000-0-US-06 Viral Chemokine-Antigen Fusion Proteins US DIV 13/890,502 Abandoned
NIAID E-136-2013-0-US-01 DEVELOPMENT AND CHARACTERIZATION OF LLAMA-DERIVED SINGLE- CHAIN ANTIBODY FRAGMENTS DIRECTED TO NOROVIRUS GI.1 AND GII.4 WITH POTENTIAL AS ORAL THERAPY FOR HUMAN NOROVIRUS DIARRHEA US 61/821,354 Abandoned
NIAID E-214-2015-0-US-01 Conformationally Stabilized RSV Pre-Fusion F Proteins US 61/644,830 Abandoned
NIAAA E-258-2012-0-US-08 Ketone Bodies To Protect Tissues From Damage By Ionizing Radiation US CON 15/403,982 10478415 Issued PDF
NIAAA E-258-2012-0-US-07 Ketone Bodies To Protect Tissues From Damage By Ionizing Radiation US National Stage 14/440,634 9579302 Issued PDF
NIAID E-214-2015-0-US-02 Conformationally Specific Viral Immunogens US ORD 13/890,226 Abandoned
NCI E-118-2013-0-US-01 Mesothelin-Specific Immunocytokine and Use Thereof US 61/820,543 Abandoned
NCI E-054-2013-1-US-01 IL-15R ALPHA FORMS, CELLS EXPRESSING IL-15R ALPHA FORMS, AND THERAPEUTIC USES OF IL-15R ALPHA AND IL-15/IL-15R ALPHA COMPLEXES US 61/820,035 Abandoned
NCI E-205-2009-0-US-08 Anti-Vascular Endothelial Growth Factor Receptor-2 Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer US DIV 13/875,560 8822196 Abandoned PDF
NCI E-085-2013-0-CA-04 Methods for Producing Enriched Populations of Tumor Reactive T Cells from Peripheral Blood CA National Stage 2902448 Issued
NCI E-059-2013-0-CA-04 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor CA National Stage 2902423 Issued
NCI E-059-2013-0-FR-19 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor FR EP 13722922.5 Issued
NCI E-059-2013-0-DE-17 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor DE EP 13722922.5 Issued
NCI E-059-2013-0-IT-21 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor IT EP 13722922.5 Issued
NCI E-059-2013-0-NL-22 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor NL EP 13722922.5 Issued
NCI E-059-2013-0-CH-16 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor CH EP 13722922.5 Issued
NCI E-059-2013-0-ES-18 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor ES EP 13722922.5 Issued
NCI E-059-2013-0-EP-06 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor EP National Stage 13722922.5 Issued
NCI E-059-2013-0-GB-20 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor GB EP 13722922.5 Issued
NCI E-085-2013-0-GB-20 Methods for Producing Enriched Populations of Tumor Reactive T Cells from Peripheral Blood GB EP 13725231.8 Issued
NCI E-085-2013-0-EP-05 Methods for Producing Enriched Populations of Tumor Reactive T Cells from Peripheral Blood EP National Stage 13725231.8 Issued
NCI E-085-2013-0-CH-16 Methods for Producing Enriched Populations of Tumor Reactive T Cells from Peripheral Blood CH EP 13725231.8 Issued
NCI E-085-2013-0-SE-24 Methods for Producing Enriched Populations of Tumor Reactive T Cells from Peripheral Blood SE EP 13725231.8 Issued
NCI E-085-2013-0-ES-18 Methods for Producing Enriched Populations of Tumor Reactive T Cells from Peripheral Blood ES EP 13725231.8 Issued
NCI E-085-2013-0-DE-17 Methods for Producing Enriched Populations of Tumor Reactive T Cells from Peripheral Blood DE EP 13725231.8 Issued
NCI E-085-2013-0-FR-19 Methods for Producing Enriched Populations of Tumor Reactive T Cells from Peripheral Blood FR EP 13725231.8 Issued
NCI E-085-2013-0-BE-15 Methods for Producing Enriched Populations of Tumor Reactive T Cells from Peripheral Blood BE EP 13725231.8 Issued
NCI E-085-2013-0-NO-23 Methods for Producing Enriched Populations of Tumor Reactive T Cells from Peripheral Blood NO EP 13725231.8 Issued
NCI E-085-2013-0-NL-22 Methods for Producing Enriched Populations of Tumor Reactive T Cells from Peripheral Blood NL EP 13725231.8 Issued